Vera Therapeutics (VERA) Operating Expenses (2020 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Vera Therapeutics was $415.76 million, up 76.1% year-over-year; for FY2025, it came in at $315.47 million, up 88.7% from FY2024.

• Annual Operating Expenses has increased for four consecutive years, with a five-year compound annual growth rate of 43.3% (FY2020 to FY2025).
• In prior years, Vera Therapeutics' Operating Expenses was $167.17 million in FY2024 (+63.9%), $102.01 million in FY2023 (+12.2%), $90.9 million in FY2022 (+164.2%) and $34.4 million in FY2021 (-34.1%).
• Quarterly Operating Expenses has run from a low of $7.25 million in Q3 2021 to a high of $125.13 million in Q1 2026 over five years.
• On a year-over-year basis, Operating Expenses has increased in each of the last nine quarters, with growth averaging 91.1% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q1 2022, with growth of 260.9%; the weakest was Q4 2021, with a decline of 61.0%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $125.13 million (Q1 2026), $94.21 million (Q4 2025) and $83.93 million (Q3 2025).